Coronavirus Update - 07th August 2020

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We remain open for business as usual and have started welcoming limited numbers of visitors to site

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

Our work and case studies

Challenge: Process chemistry route to API required hydrogenation, then salt formation. The hydrogenation product was chemically unstable until the salt was formed. On a large scale, this was adequately controlled.

In radiochemical trials, the larger dilution and higher catalyst loading required for the very small-scale synthesis led to increased degradation of the unstable intermediate and unacceptable yield.


US Biopharmaceutical Company


A flow hydrogenation reactor was used; as the chemically unstable product was formed it was fed directly into the salt formation vessel. This greatly reduced degradation.

Successful [14C]synthesis was carried out to support both non-clinical and clinical trials. 


ICMS Radiosynthesis Case Study